MicrobiotiX concludes sentinel cohort in Phase I trial of MP101

MicrobiotiX has completed the sentinel cohort of its Phase I, first-in-human clinical trial evaluating MP101 in adult patients with pneumonia caused by Pseudomonas aeruginosa. The double-blind, placebo-controlled and randomised trial aims to enrol 18 adults with acute P. aeruginosa pneumonia. MicrobiotiX CEO Dr Dongeun Yong gives a tour of the company’s good manufacturing practice facility, where the clinical material used in the MP101 trial was manufactured. Credit: MicrobiotiX/Globe Newswire. MicrobiotiX has completed the sentinel cohort of its Phase I, first-in-human clinical trial evaluating MP101 in adult patients with pneumonia caused by Pseudomonas aeruginosa. Following a 72-hour tolerability and safety assessment,…

Source: Clinical Trials Arena